Vericel Reports Strong Preliminary 2025 Revenue and Profitability, Anticipates Continued Growth

summarizeSummary

Vericel Corporation announced strong preliminary, unaudited financial results for fiscal year 2025, including $276 million in total revenue and continued GAAP net income profitability, alongside positive operational updates and an optimistic outlook for 2026.

check_boxKey Events

• Strong Preliminary 2025 Financials

  Reported approximately $276 million in total net revenue and $239.5 million in MACI net revenue for fiscal year 2025.

• Consistent Profitability and Growth

  Achieved GAAP net income profitability for the second consecutive year and MACI revenue growth of 20% or more for the third consecutive year.

• Robust Operational Performance

  Recorded the highest number of MACI implants, implanting surgeons, and biopsies in any quarter since launch in Q4 2025.

• Healthy Balance Sheet

  Ended 2025 with $200 million in cash and investments and no debt.

auto_awesomeAnalysis

The preliminary 2025 financial results indicate robust performance, with total revenue reaching approximately $276 million and MACI revenue growing over 20% for the third consecutive year. Achieving GAAP net income profitability for the second year and maintaining a strong cash position with no debt highlights the company's financial health. Operational milestones, such as record MACI implants and surgeon training, coupled with the initiation of a new clinical study and progress on manufacturing expansion, demonstrate strong execution and future growth potential. The CEO's optimistic outlook for continued high revenue growth and profitability in 2026 suggests positive momentum for investors.